Around 700 generic medicines have been banned from marketing by the European Union over alleged manipulation of clinical trials which was conducted by GVK Biosciences, an Indian pharmaceutical research company.

The ban will be applicable to all 28 member nations, according to Germany's drug regulator, the Federal Institute for Medicines and Medical Products.

It will come into effect on August 21.

GVK Biosciences, vehemently denying the allegations, offered to conduct fresh studies of the medicines involved at its own cost.